Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Nov;30(11):3142-3149.
doi: 10.1038/s41591-024-03202-4. Epub 2024 Aug 30.

Electronic nudges for sustained influenza vaccination uptake in older adults: the nationwide randomized NUDGE-FLU-2 trial

Affiliations
Randomized Controlled Trial

Electronic nudges for sustained influenza vaccination uptake in older adults: the nationwide randomized NUDGE-FLU-2 trial

Niklas Dyrby Johansen et al. Nat Med. 2024 Nov.

Abstract

Digital letter interventions have proven effective in increasing influenza vaccination rates. In this trial, we sought to further refine these strategies and investigated whether the effectiveness of the strategies could be sustained across consecutive influenza seasons. We enrolled all eligible Danish citizens 65 years of age or older in a nationwide registry-based randomized implementation trial during the 2023-2024 influenza season. Households of participants were randomly assigned in a 2.45:1:1:1:1:1:1 ratio to usual care or six different behaviorally informed electronic letter-based nudges delivered before the influenza vaccination period. The primary endpoint was receipt of influenza vaccination. Statistical analyses accounted for household-level clustering. A total of 881,373 participants (mean age 74.1 ± 6.5 years, 52.1% female) were randomized across 649,487 households. The primary endpoint was met; influenza vaccination rates were higher in the pooled intervention letter group compared to usual care (76.32% versus 76.02%; difference, 0.31 percentage points; 99.29% confidence interval, 0.00-0.61; P = 0.007). Although no individual letter significantly increased influenza vaccination rates, the directionality of effect was consistent across all letters. Effectiveness was particularly pronounced in participants who had not received influenza vaccination during the preceding season (Pinteraction = 0.010). Effectiveness was consistent regardless of whether participants had received a similar electronic letter-based nudge in the preceding season (Pinteraction = 0.26). In summary, electronic letter-based nudges successfully increased influenza vaccination among older adults, and our results suggest that these highly scalable strategies can be implemented effectively and safely across consecutive vaccination seasons.ClinicalTrials.gov registration: NCT06030726 .

PubMed Disclaimer

Conflict of interest statement

Competing interests M.V. has received research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer, Baxter Healthcare, Boehringer Ingelheim, Chiesi, Cytokinetics, Lexicon Pharmaceuticals, Novartis, Novo Nordisk, Pharmacosmos, Relypsa, Roche Diagnostics, Sanofi and Tricog Health; has speaker engagements with AstraZeneca, Boehringer Ingelheim, Novartis and Roche Diagnostics; and participates on clinical trial committees for studies sponsored by AstraZeneca, Bayer, Galmed, Occlutech, Novartis and Impulse Dynamics. A.S.B. has received research grant support to his institution from the National Institutes of Health/National Heart, Lung, and Blood Institute, the National Institutes of Health/National Institute on Aging, the American College of Cardiology Foundation and the Centers for Disease Control and Prevention and has received consulting fees from Sanofi Pasteur and Novo Nordisk. B.L.C. has received consulting fees from Amgen, Cardurion, Corvia, Myokardia and Novartis. C.S.L. has received speaker fees and served on advisory boards for GlaxoSmithKline, Merck Sharp & Dohme, Pfizer, Takeda and Valneva. L.K. has received speaker fees from Novo Nordisk, Novartis, AstraZeneca, Boehringer Ingelheim and Bayer. S.D.S. has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon, Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Eli Lilly, Mesoblast, MyoKardia, National Institutes of Health/National Heart, Lung, and Blood Institute, Neurotronik, Novartis, Novo Nordisk, Respicardia, Sanofi, Theracos and US2.AI and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi Sankyo, GlaxoSmithKline, Eli Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, Sarepta, Lexicon, Anacardio, Akros and Puretech Health. T.B.-S. has served as chief investigator of the Sanofi-financed NUDGE-FLU trial, the Sanofi-financed DANFLU-1 trial and the Sanofi-financed DANFLU-2 trial; served as steering committee member of the Amgen-financed GALACTIC-HF trial, the Boston Scientific–financed LUX-Dx TRENDS trial and the Boehringer Ingelheim–financed EASi-KIDNEY trial; served on advisory boards for Sanofi, GlaxoSmithKline, Amgen and CSL Squirus; received speaker honoraria from Bayer, GlaxoSmithKline, Novartis, GE Healthcare and Sanofi; consulted for Novo Nordisk, IQVIA and Parexel; and received research grants from GE Healthcare, Sanofi, Boston Scientific, AstraZeneca and Novo Nordisk. All other authors declare no competing interests.

References

    1. World Health Organization. Influenza (Seasonal). https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal) (2023).
    1. Gross, P. A., Hermogenes, A. W., Sacks, H. S., Lau, J. & Levandowski, R. A. The efficacy of influenza vaccine in elderly persons. Ann. Intern. Med. 123, 518–527 (1995). - DOI - PubMed
    1. Rondy, M. et al. Effectiveness of influenza vaccines in preventing severe influenza illness among adults: a systematic review and meta-analysis of test-negative design case–control studies. J. Infect. 75, 381–394 (2017). - DOI - PubMed - PMC
    1. McLean, H. Q. Interim estimates of 2022–23 seasonal influenza vaccine effectiveness—Wisconsin, October 2022–February 2023. MMWR Morb. Mortal. Wkly Rep. 72, 201–205 (2023). - DOI - PubMed - PMC
    1. Fröbert, O. et al. Influenza vaccination after myocardial infarction: a randomized, double-blind, placebo-controlled, multicenter trial. Circulation 144, 1476–1484 (2021). - DOI - PubMed

Publication types

Substances

Associated data